Morgan Stanley analyst Thomas Wrigglesworth initiated coverage of Novonesis (NVZMY) with an Overweight rating and DKK 577 price target Novonesis is a “high-quality biotech-based growth compounder” with structural end market drivers to sustain above-peer sales growth and margins, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVZMY: